Tuesday, October 30, 2012

Insurance Policies Favoring Compounded Drugs For High-Risk Pregnancies Draw Scrutiny


OCT 30, 2012
When a brand-name drug to help prevent premature births was approved last year, its $1,500-a-dose-price alarmed state and private sector insurance officials.
Many restricted use of the FDA-approved Makena in favor of $20- to $40-a-dose versions that had been made for years by pharmacies, saying that would give more women access to the treatment. Federal officials, sympathetic to such arguments, allowed the pharmacies to continue making the unapproved drugs.

Clink here to continue reading

No comments: